This pro‐tumorigenic effect is postulated to converge with the effect of Cabozantinib target RET in ccRCC and GNAS gain may thus be associated with sensitivity to the drug16 (Figure 6). The gene discussed is RET; the disease is nonpapillary renal cell carcinoma.